Oasmia in Barcelona
September 27 2007
A big step for Oasmia in Barcelona
This Thursday results from a phase I/II study with the cancer drug Paclical® was presented at the European Cancer Conference (ECCO 14) in Barcelona.
- Paclical® is a new interesting cancer drug. Compared to conventional therapy with paclitaxel Paclical® can be given in a shorter time and without preventive medication against hypersensitivity reactions, says Niklas Loman at Lunds University Hospital, principal investigator for the clinical study.
The results of the study and the generated interest for Paclical® at the conference in Barcelona is a big step forward for Oasmia and confirms further the company´s strong product portfolio.
The press release is available in PDF-format here.
